Pancreatic cancer: challenges and opportunities
- PMID: 30463539
- PMCID: PMC6249728
- DOI: 10.1186/s12916-018-1215-3
Pancreatic cancer: challenges and opportunities
Abstract
Pancreatic cancer is the fourth leading cause of cancer-related death in the United States, with increasing incidence. The mortality rate of pancreatic cancer is rising rapidly, and is projected to be the second most common of all malignant tumors by 2030. However, the diagnosis and therapy of pancreatic cancer remain a formidable challenge. Recently, enormous efforts have been made to develop several new methods for the early diagnosis and treatment of pancreatic cancer. We briefly introduce the most groundbreaking advances in pancreatic cancer diagnosis and clinical treatment strategies over the past 15 years, including surgery, chemotherapy, endoscopic therapy, immunotherapy and personalized medicine. The signaling pathways that are altered in the progression of pancreatic cancer, which may be used as therapeutic targets, are also discussed.
Keywords: Diagnosis; Pancreatic cancer; Therapy.
Conflict of interest statement
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Similar articles
-
Personalized therapy for pancreatic cancer: Do we need better targets, arrows, or both?Discov Med. 2016 Feb;21(114):117-23. Discov Med. 2016. PMID: 27011047 Review.
-
Pancreatic cancer subtyping - the keystone of precision treatment.Front Immunol. 2025 Apr 8;16:1563725. doi: 10.3389/fimmu.2025.1563725. eCollection 2025. Front Immunol. 2025. PMID: 40264765 Free PMC article. Review.
-
Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field.Cancer Res. 2017 Mar 1;77(5):1060-1062. doi: 10.1158/0008-5472.CAN-16-2452. Epub 2017 Feb 16. Cancer Res. 2017. PMID: 28209609
-
[Significance of precision medicine in pancreatic cancer prevention and treatment].Zhonghua Zhong Liu Za Zhi. 2016 Mar 23;38(3):161-4. doi: 10.3760/cma.j.issn.0253-3766.2016.03.001. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 26988819 Chinese.
-
[Pancreatic Cancer in the Year 2018 - Room for Precision Medicine?].Dtsch Med Wochenschr. 2018 Aug;143(15):1109-1112. doi: 10.1055/a-0542-4310. Epub 2018 Jul 30. Dtsch Med Wochenschr. 2018. PMID: 30060283 German.
Cited by
-
Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.Mol Cancer. 2023 Jan 12;22(1):8. doi: 10.1186/s12943-022-01696-5. Mol Cancer. 2023. PMID: 36635659 Free PMC article. Review.
-
Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients.Front Pharmacol. 2023 Sep 7;14:1244752. doi: 10.3389/fphar.2023.1244752. eCollection 2023. Front Pharmacol. 2023. PMID: 37745080 Free PMC article.
-
A signature of 18 immune-related gene pairs to predict the prognosis of pancreatic cancer patients.Immun Inflamm Dis. 2020 Dec;8(4):713-726. doi: 10.1002/iid3.363. Epub 2020 Oct 31. Immun Inflamm Dis. 2020. PMID: 33128857 Free PMC article.
-
Ratio of CA19-9 level to total bilirubin as a novel prognostic indicator in patients with pancreatic head carcinoma following curative resection.Gland Surg. 2021 Mar;10(3):980-991. doi: 10.21037/gs-20-720. Gland Surg. 2021. PMID: 33842242 Free PMC article.
-
GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression.Front Cell Dev Biol. 2021 Apr 29;9:640391. doi: 10.3389/fcell.2021.640391. eCollection 2021. Front Cell Dev Biol. 2021. Retraction in: Front Cell Dev Biol. 2023 Sep 15;11:1260259. doi: 10.3389/fcell.2023.1260259. PMID: 33996796 Free PMC article. Retracted.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous